- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Generalised myasthenia gravis (gMG)
- Meeting Date: March 2025
- Public Summary Document (PSD) March 2025 PBAC Meeting - (PDF)
- Public Summary Document (PSD) March 2025 PBAC Meeting - (Word)
Zilucoplan – March 2025
Zilucoplan; Solution for injection 16.6 mg in 0.416 mL (as tetrasodium) pre-filled syringe, Solution for injection 23 mg in 0.574 mL (as tetrasodium) pre-filled syringe, Solution for injection 32.4 mg in 0.810 mL (as tetrasodium) pre-filled syringe; Zilbrysq®
Last updated
12 March 2025
